GVAX-CSF, a vaccine that expresses GM-CSF and induces an immune response against the tumor, inhibited of tumor growth in animal and cell models, but failed to demonstrate efficacy in a phase II trial compared to single-agent chemotherapy [60]. The gene discussed is CSF2; the disease is neoplasm.